Revenues (Tables)

6 Months Ended

Jun. 30, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product.  The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
OraQuick®	$	15,791	$	16,530	$	28,796	$	30,639
Oragene®		15,368		15,215		32,456		25,154
Intercept®		2,154		2,239		4,069		4,166
Histofreezer®		1,973		2,570		4,327		5,250
Other products		3,532		2,578		7,488		5,405
Net product revenues		38,818		39,132		77,136		70,614
Royalty income		2,092		-		3,694		-
BARDA funding		1,920		1,044		3,458		2,108
Charitable support reimbursement		795		-		1,324		-
Other revenues		4,807		1,044		8,476		2,108
Net revenues	$	43,625	$	40,176	$	85,612	$	72,722

Revenues by geographic area.  The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
United States	$	31,991	$	28,954	$	62,977	$	49,808
Europe		2,308		2,436		5,205		5,561
Other regions		9,326		8,786		17,430		17,353
	$	43,625	$	40,176	$	85,612	$	72,722

ASU 2014-09 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Summary of Impact of New Revenue Standard Adjustment on Opening Balance Sheet

The following table summarizes the impact of the new revenue standard adjustment on our opening balance sheet:

	Balance at			New Revenue			Balance at
	December 31, 2017			Standard Adjustment			January 1, 2018
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Deferred revenue		1,314			75			1,389
STOCKHOLDERS' EQUITY
Accumulated deficit		(119,510	)		(75	)		(119,585	)